Thrombophilia Global Market Report 2024

The thrombophilia market size has grown strongly in recent years. It will grow from $15.97 billion in 2023 to $17.23 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth observed during the historic period can be credited to several factors, including heightened awareness, extensive research and development in anticoagulant therapies, the aging population demographic, advancements in genetic research, and a notable rise in the occurrence of thrombotic disorders.

The thrombophilia market size is expected to see strong growth in the next few years. It will grow to $23.31 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The anticipated growth in the forecast period is linked to various factors, including the advent of personalized medicine, the introduction of innovative therapies, the integration of artificial intelligence into healthcare practices, the impact of healthcare policies and regulations, and an upsurge in patient education and empowerment. Significant trends expected in this period encompass advancements in technology, the expanded utilization of telemedicine, an upward trend in incidence rates, ongoing developments in biopharmaceuticals, and an increase in collaborative research initiatives.

The anticipated growth in the elderly population is poised to drive the expansion of the thrombophilia market in the future. The term 'elderly population' refers to individuals aged 65 and older, and their increasing proportion within the overall population signifies a demographic shift. Thrombophilic risk factors are prevalent in the elderly, providing a means to identify those at risk for adverse clinical outcomes. Consequently, the rise in the elderly population is expected to fuel demand for thrombophilia drugs. As of 2022, data from America’s Health Rankings indicates that more than 56 million adults aged 65 and older constitute approximately 16.9% of the total US population. Projections for 2030 estimate over 73.1 million older individuals, coinciding with the aging of the baby boomer generation. This demographic trend is a key driver propelling the growth of the thrombophilia market.

The increasing prevalence of thrombophilic conditions is anticipated to contribute significantly to the growth of the thrombophilia market in the years ahead. Thrombophilic diseases, characterized by an elevated predisposition to blood clot formation (thrombosis), play a crucial role in shaping the thrombophilia market landscape, influencing diagnosis, treatment approaches, and ongoing research. For example, in August 2023, data from the Nuffield Trust revealed that the UK had the highest number of cases of Deep Vein Thrombosis (DVT) among eight nations providing data. In 2021, there were 352 cases, increasing to 377 for every 100,000 hospital discharges in 2022. This surge in the prevalence of thrombophilic conditions serves as a key factor driving the thrombophilia market.

Technological advancements are a predominant trend in the thrombophilia market, with major companies actively engaged in developing innovative technologies to maintain and enhance their market positions. In 2021, the University of Oslo, a Norway-based public research university, introduced a groundbreaking technology known as super albumin, potentially revolutionizing the creation of long-acting drugs for individuals with hemophilia, a condition affecting the blood's clotting ability. The university's research group employed an advanced biomedical technique to produce coagulation factors with significantly extended half-lives. Super albumin, a protein variant developed through this research, can be combined with protein-based drugs to prolong their bloodstream half-life, showcasing the potential impact of cutting-edge biomedical approaches in the thrombophilia market.

Major companies in the thrombophilia market are strategically pursuing partnerships to advance the development of biosynthetic heparin. Strategic partnerships involve leveraging each other's strengths and resources for mutual benefits and success. For example, in January 2022, Optimvia, LLC, a US-based biotechnology company, announced a partnership with Ginkgo Bioworks with the aim of enhancing the efficiency of biosynthetic heparin synthesis. Optimvia plans to utilize Ginkgo's cell and enzyme engineering systems, along with its fermentation manufacturing capabilities, to expedite the improvement of its biosynthetic heparin production method. The collaboration aims to create commercially viable, cost-effective, and safe biosynthetic heparin, potentially reducing the global dependence on heparin sourced from livestock. Ginkgo Bioworks, a US-based company specializing in cell programming, provides a platform to support this innovative partnership in the thrombophilia market.

In March 2022, Pfizer Inc., a prominent US-based pharmaceutical company, successfully completed the acquisition of Arena Pharmaceuticals for a substantial sum of $6.7 billion. As a result of this acquisition, Arena Pharmaceuticals has now become a subsidiary of Pfizer. This strategic move is anticipated to foster innovations aimed at enhancing the lives of individuals grappling with immuno-inflammatory disorders. Arena Pharmaceuticals, Inc., the acquired entity, is based in the United States and is dedicated to developing treatments for thromboembolic disorders affecting the arterial blood vessels. The acquisition reflects Pfizer's commitment to expanding its portfolio and capabilities in the field of pharmaceuticals, particularly in addressing disorders related to the immune and inflammatory systems.

Major companies operating in the thrombophilia market report are Pfizer Inc., F. Hoffmann-La Roche Limited, Mylan N.V., Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Aspen Insurance Holdings Limited, Sanofi SA, Eisai Co. Limited, Boehringer Ingelheim GmbH, Siemens, LabCorp, Instrumentation Laboratory SpA, Johnson & Johnson, Laurus Lab, Bristol-Myers Squibb, Roche, Abbott, C. H. Boehringer Sohn, Portola Pharmaceuticals, Daiichi Sankyo, Bayer Group, GlaxoSmithKline plc, CSL Behring.

North America was the largest region in the thrombophilia market in 2023. The regions covered in the thrombophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the thrombophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary thrombophilia types encompass factor V Leiden, prothrombin 20210, antiphospholipid syndrome, among others. Factor V Leiden involves a mutation in one of the blood-clotting factors. Treatment options include medications such as Heparin, Warfarin, and others, administered through various routes including oral and parenteral. End-users of these treatments span across hospitals, home health agencies, specialty centers, and similar entities.

The thrombophilia market research report is one of a series of new reports that provides thrombophilia market statistics, including thrombophilia industry global market size, regional shares, competitors with a thrombophilia market share, detailed thrombophilia market segments, market trends and opportunities, and any further data you may need to thrive in the thrombophilia industry. This thrombophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.